Since the correlation between some blood- and CSF-based biomarkers is suboptimal, especially for Aβ42 [10, 43] and GFAP [44], it is possible that BBM may provide different and/or complementary insights on the neural alterations associated with AD in different disease stages. The gene discussed is GFAP; the disease is Alzheimer disease.